Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORNEO 01: Neoadjuvant Hormone Therapy for Extensive DCIS
NCT04666961Phase 2Recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Feb 2021
- Primary completion
- Aug 2024
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen and anastrozole in ductal carcinoma in situ (DCIS), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Efficacy of neoadjuvant hormonotherapy at 6 months. Started Feb 2021; status: recruiting.
02
Drugs
tamoxifenanastrozole
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT04666961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666961.